График акции Regulus Therapeutics Inc.
Расширенный график
Простой график
О компании
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. Подробнее| Выручка | 0.0068 |
|---|---|
| EBITDA | -0.0159 |
| Число акций ао | 0.01896 млрд |
| P/S | 2.75 |
| P/BV | 0.94 |
| EV/EBITDA | 0.0425 |
| Цена ао | 2.85 |
| ISIN | US75915K3095 |
| Сайт | https://www.regulusrx.com |
| Валюта | usd |
| IPO date | 2012-10-04 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Изменение цены за день: | -1.84% (1.63) |
|---|---|
| Изменение цены за неделю: | -0.6211% (1.61) |
| Изменение цены за месяц: | +2.56% (1.56) |
| Изменение цены за 3 месяца: | -9.09% (1.76) |
| Изменение цены за полгода: | -40.74% (2.7) |
| Изменение цены за год: | +17.65% (1.36) |
| Изменение цены за 3 года: | +116.89% (0.7377) |
| Изменение цены за 5 лет: | +156.16% (0.6246) |
| Изменение цены с начала года: | +22.14% (1.31) |
|
|
Недооценка
|
Эффективность
|
|||||||||||||||||||||||||||||||||||||
Дивиденды
|
Долг
|
Импульс роста
|
|||||||||||||||||||||||||||||||||||||
| Институционалы | Объем | Доля, % |
|---|---|---|
| Federated Hermes, Inc. | 3875578 | 5.92 |
| FMR, LLC | 2922600 | 4.46 |
| NEA Management Company, LLC | 1945579 | 2.97 |
| DAFNA Capital Management, LLC | 1111049 | 1.7 |
| Vanguard Group Inc | 286431 | 0.44 |
| Victory Capital Management Inc. | 271736 | 0.42 |
| Sarissa Capital Management, LP | 185183 | 0.28 |
| Exome Asset Management LLC | 178404 | 0.27 |
| Geode Capital Management, LLC | 122521 | 0.19 |
| Renaissance Technologies, LLC | 54600 | 0.08 |
| ETF | Доля, % | Доходность за год, % | Дивиденды, % |
|---|---|---|---|
| Avantis U.S Small Cap Equity ETF | 0.00491 | 29.82202982203 | 1.68271 |
| ProShares Hedge Replication ETF | 0.00063 | 5.5087969920031 | 1.47892 |
| iShares Micro-Cap ETF | 0.02905 | 35.054312164247 | 1.54048 |
| ProShares UltraPro Russell2000 | 0.00248 | 81.385281385281 | 1.47873 |
| Vanguard Russell 3000 ETF | 0 | 35.867021276596 | 1.43817 |
| Vanguard Russell 2000 Growth ETF | 0 | 34.809548656405 | 0.60264 |
| Vanguard Russell 2000 ETF | 0 | 32.304263853811 | 1.48801 |
| Руководитель | Должность | Оплата | Год рождения |
|---|---|---|---|
| Mr. Joseph P. Hagan M.B.A. | CEO & Director | 958.23k | 1969 (55 лет) |
| Ms. Crispina Calsada CPA | Chief Financial Officer | 579.3k | 1970 (54 года) |
| Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 575.94k | 1961 (63 года) |
| Mr. Daniel J. Penksa | VP of Finance & Controller | N/A | 1986 (38 лет) |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | N/A | |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer | N/A | |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | N/A | 1969 (55 лет) |
| Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | N/A |
Адрес: United States, San Diego. CA, 4224 Campus Point Court - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.regulusrx.com
Сайт: https://www.regulusrx.com
